3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow

Eli Lilly is highlighted as a GLP-1 leader, with Mounjaro sales up 99% in 2025 and Zepbound sales up 175%, while Q1 sales rose 125% and 80%, respectively. The company is also expanding its GLP-1 pill efforts and deploying drug profits into acquisitions, including moves to build an infectious disease business. The article frames Lilly as expensive at 40x earnings, but still attractive for growth investors given strong execution and future pipeline optionality.

Analysis

LLY is functioning less like a single-drug story and more like a re-rating of the entire obesity franchise into a platform business. The second-order winner is not just the branded GLP-1 peer set; it is the contract manufacturing, fill-finish, and cold-chain ecosystem that has to scale alongside volume, while the likely loser is any smaller increasable competitor that lacks distribution depth, payer leverage, or a credible oral pipeline. The market is still underestimating how much of LLY’s current cash generation can be converted into option value through BD before the patent clock becomes the dominant variable.

The key risk is that the current multiple implicitly prices in both sustained share gains and no meaningful erosion in pricing power. That combination is fragile over a 12-24 month horizon if oral competition broadens the market faster than supply expands, because the first large payer re-contracting cycle will shift the debate from “who is growing fastest” to “who is defending net price best.” Any hint that the oral format is commoditizing faster than expected would pressure the premium multiple before it shows up in headline revenue.

The contrarian take is that the market is extrapolating current GLP-1 momentum into a durable moat, when the real moat may be operational execution and manufacturing capacity rather than molecule quality. That matters because operational moats are easier to copy than true IP barriers, especially once patient access improves and prescribers normalize switching. In that setup, the best long may be LLY versus weaker-capitalized competitors, but the worst long may be the sector outright if investors start paying growth multiples for what becomes a capacity and reimbursement race.

Key Decisions for Investors

• Maintain a long LLY / short NVO pair over the next 3-6 months: LLY has the better near-term execution and capital-allocation narrative, while NVO is more exposed to the market discounting oral-formulation differentiation being less durable than expected.
• Buy LLY on 5-10% pullbacks rather than chasing strength; use a 6-12 month horizon and target a 15-20% upside if earnings revisions continue to outpace multiple compression.
• Hedge a fresh LLY long with 3-6 month put spreads if implied volatility is depressed; the main downside catalyst is payer pushback or any sign of oral GLP-1 share cannibalization, which can hit the multiple before fundamentals roll over.
• Overweight the GLP-1 supply chain selectively, especially manufacturing-enabled healthcare names, for a 12-18 month trade; capacity expansion is the less obvious beneficiary if demand remains structurally above consensus.